Sarepta Therapeutics (SRPT) Other Non Operating Income (2010 - 2026)

Sarepta Therapeutics has reported Other Non Operating Income for 17 years, with the latest figure at -$15.0 million in Q2 2026.

• On a quarterly basis, Other Non Operating Income fell 139.52% year-over-year to -$15.0 million in Q2 2026; TTM through Jun 2026 was -$49.6 million, a 113.82% decrease from a year earlier, with the FY2025 full-year figure at -$19.3 million, down 145.22% from the prior year.
• Other Non Operating Income was -$15.0 million for Q2 2026 at Sarepta Therapeutics, up from -$15.3 million in the prior quarter.
• The five-year high for Other Non Operating Income was $138.6 million in Q3 2025, with the low at -$387.3 million in Q1 2023.
• Average Other Non Operating Income over 5 years is -$37.1 million, with a median of -$13.7 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Other Non Operating Income tumbled 39849.36% in 2022, then surged 1073.58% in 2025.
• Over 5 years, Other Non Operating Income stood at -$125.4 million in 2022, then surged by 90.17% to -$12.3 million in 2023, then soared by 181.59% to $10.1 million in 2024, then slumped by 1669.33% to -$157.9 million in 2025, then soared by 90.48% to -$15.0 million in 2026.
• The last three Other Non Operating Income figures came in at -$15.0 million (Q2 2026), -$15.3 million (Q1 2026), and -$157.9 million (Q4 2025), per Business Quant data.